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Abstrak
Latar belakang: Penelitian ini untuk membandingkan efikasi dan keamanan Artemisinin-Napthoquine 
(AN) dengan dosis tunggal dan obat pilihan ACT lain, dengan Dihydroartemisinin-Piperaquine (DHP) 
pada pengobatan P.vivax.
Metode: Penelitian ini adalah studi randomisasi terbuka dengan subyek direkrut mulai tahun 2007 – 2008 
dari RS St Gabriel, Maumere dan RS Polisi, RS Angkatan Darat dan RS Angkatan Laut di Jayapura. 
Penelitian ini merupakan bagian dari penelitian utama yang sudah dipublikasi sebelumnya. Efikasi 
dinyatakan dengan  ketiadaan klinis dan parasit malaria sampai dengan hari ke 42, disebut Adequate 
Clinical and Parasitological Response (ACPR). Keamanan dinyatakan sebagai kejadian sampingan yang 
ditemukan pada setiap kunjungan ulang yang tidak dilaporkan sebelumnya pada hari rekrutmen (h0). 
Hasil: Total 158 subyek dianalisis. Sejumlah 80 subyek direkrut pada kelompok AN dan 78 dengan DHP. 
Median Parasite Clearance Estimator (PCE) yaitu 2,32 (kisaran: 1,42 – 7,78; IQR: 1,99 – 2,82) jam pada 
AN dan 2,05 (kisaran: 1,30 – 8,30; IQR: 1,82 – 2,46) jam pada DHP. Parasite clearance sudah terjadi dalam 
64 jam. Adequate clinical parasitological response (ACPR) at day 42 was 100% (95% CI: 95,2-100) pada 
AN, dan 100% (95% CI: 94,9-100) pada DHP. Kejadian Sampingan ditemukan ringan dan dapat ditoleransi. 
Kesimpulan: Kedua obat memiliki efikasi dan keamanan yang sebanding untuk pengobatan malaria vivaks 
dewasa. Walaupun pembersihan parasit AN lebih lama dibandingkan DHP, 100% pembersihan terjadi 
pada kedua kelompok pengobatan dalam 64 jam. (Health Science Journal of Indonesia 2015;6:92-8)
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Abstract
Background: This study was to compare the efficacy and safety between Artemisinin-Napthoquine (AN) 
as a single dose as well as an alternative drug, and Dihydroartemisinin-Piperaquine (DHP) as a three-day 
standard regimen on P. vivax infection. 
Methods: This was an open randomized study performed during the period of April 2007- March 2008 in 
three Armed Forces Hospitals in Jayapura, Papua Province, and one private hospital in Maumere, East Nusa 
Tenggara Province. This study was a part from previously published study for any malaria infection. Efficacy 
was the absence of clinical and parasitological malaria until day 42, performed as Adequate Clinical and 
Parasitological Response (ACPR). Safety was performed based on adverse event in any day of follow up 
which never reported at day recruitment (d0). 
Results: This study analyses 158 P. vivax cases. A total 80 subjects were treated with AN and 78 with DHP. 
The median Parasite Clearance Estimator (PCE) was 2.32 (range: 1.42 – 7.78; Interquartile Range (IQR): 1.99 
– 2.82) hours in AN and 2.05 (range: 1.30 – 8.30; IQR: 1.82 – 2.46) hours in DHP group. The parasite clearance 
was complete by 64 hours. The ACPR was 100% (95% Confidance Interval (CI): 95.2-100) in the AN, and 
100% (95% CI: 94.9-100) in the DHP group. Both drugs have similar mild and tolerated adverse events. 
Conclusions: Both drugs have similar efficacy and safety for the treatment of P. vivax in adults. Although 
AN has took longer PCE compared to DHP, 100% clearance was achieved in both groups in 64 hours. 
(Health Science Journal of Indonesia 2015;6:92-8)
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Malaria, the old disease caused by Plasmodium species 
has been difficult to control until now. P. falciparum and 
P. vivax infection (55%: 45%) comprise the main malaria 
infections  in Indonesia.1 Although P. vivax is usually 
associated with uncomplicated malaria, some cases may 
become severe.1-3 Malaria is a major health issue in the 
eastern part of the Indonesia. Annual Parasite Incidence 
(API) in Papua and East Nusa Tenggara was reported as 
177 and 81cases per 100000 people in 2007.4
Dihydroartemisine-Piperaquine (DHP) which has been 
widely used since 2009 has become the new standard 
regimen of antimalarial therapy in Indonesia and has 
demonstrated better efficacy and safety against P. vivax 
in comparison with AAQ.4-6 DHP is a fixed once-daily 
dose taken for three days. The drug is well-tolerated and 
has better compliance than AAQ in Indonesia.5 Drug 
compliance is a complex issue for antimalarial regimens 
and can be associated with early treatment failure (e.g. 
Chloroquine).7 Although safe and efficacious treatment 
regimens of only three days are available compliance 
remains an issue.8-10 An alternative drug that could be 
taken in a single dose and directly observed could 
improve compliance and prevent treatment failure 
and relapse. Additionaly relapses an important 
issue and difficult to distinguish from reinfection or 
recrudescence in P. vivax infection.
Artemisinin-Napthoquine (AN) is a alternative drug 
that can be given in a single dose and is reported to 
have better efficacy and safety for P. falciparum.11.12 
Artesunate-Amodiaquine (AAQ) was the first ACT 
approved in Indonesia since 2004 but the efficacy 
for P.vivax is 52%.5 AN was developed  in China in 
the1990s and is known to be more efficacious than 
artemisinin or piperaquine monotherapy.12 The API 
decreased was shown in Papua and East Nusa Tenggara 
in 2011 after Artemisinin Combination Therapy 
(ACT) was adopted as a standard regimen.6.13.14
In this report, we compared the efficacy and safety 
profile of DHP and AN in treating P. vivax malaria 
patients in Indonesian hospitals. We compared the 
clinical symptoms from day 0 to 42 days and the 
recurrence of parasitemia from day 7 until day 42.
METHODS
Study Design
This was an open-label multi-center randomized 
trial. phase 3 comparative study to determine 
efficacy and safety of a single dose AN vs DHP 
as a three-day standard regimen in adults with 
uncomplicated P.vivax. We evaluated 158 subjects 
infected with P. vivax alone. Inclusion criteria were 
previously reported.15 Subjects infected by P.vivax 
were required to have circulating asexual parasite 
levels ≥ 250 parasite/ul. 
Study Setting
The study was performed during the period of April 
2007- March 2008 in three Armed Forces Hospitals 
in Jayapura, Papua Province and one private hospital 
in Maumere, Sikka District, East Nusa Tenggara 
Province. All of the subject were uncomplicated P. 
vivax cases but all of them were hospitalized because 
AN was a new drug therefore the subjects received 
DHP had the same treatment as AN. In Papua 
province, chloroquine resistance, cross-resistant 
amodiaquine, and low AAQ efficacy and safety for 
P.vivax had been previously reported.3.5.16,17
Study Drugs
The AN was manufactured by Kunming 
Pharmaceutical Corporationas Arco™. One tablet 
contains 250 mg of Artemisinin and 100 mg of 
Naphthoquine (equivalent with 156.6 mg of Phosphate 
Napthoquine). The drug was compared with DHP. 
Duo-Cotecxin ™ produced by Beijing Holley Cotex 
Pharmaceutical Co.Ltd; one tablet contains 40 mg 
and 320 mg of dihydrortemisinin piperaquine. Four 
tablets of Artemisinine-Napthoquine (Arco™) were 
administered to theAN subjects by investegator 
on recruitment day (D0) only. Dihydroartemisin-
piperaqine (Duo-Cotecxin™) was given to DHP 
subjects by investigator in one dose a day for three 
days; one dose was 3 tablets for people with body 
weight of 35-60 kg or 4 tablets for body weight of 
>60 kg. Primaquine with 0.5 mg  per kg body weight 
was given to all subject when recurrence occurred 
or on the last day of the study  (Day 42). All drug 
treatments on all subjects were directly observed.
Study Procedure
As detailed previously,15 parasite asexsual and 
gametocyte count was measured on day 0 at hour 
0 (h0) then measured at eight-hour intervals for the 
first three days (at 8, 16, 24, 32, 40, 48, 56, 64, and 
72 hours). Measuring the parasite was conducted 
on follow up schedule at day 7, 14, 21, 28, 35 and 
42. The blood blot slide was taken and read by 
trainned microscopist. The asexsual parasite count 
was calculated based on total parasite per 200 µl 
leucocyte multiplied by 5000 µl leucocyte.15 While 
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the gametocyte was calculated  per 2000 ul leucocyte 
multiplied by 5000 µl leucocyte. All subjects were 
hospitalized until day 3 to observe adverse events 
even though the parsitemia was cleared.
History taking. clinical examination and adverse events 
were all performed on the initial recruitment day 0 (d0). 
and on follow-up visits (d1, d2, d3, d7, d14, d21, d28, 
d35). and until the last day (d42) or days of reccurence. 
Study outcomes and Data Analysis
Efficacy was defined according to the WHO 2009 as a 
Adequate Clinical and Parasitology Response (ACPR) 
protocol at D42, which is evaluated based on intention 
to treat (ITT) and Per Protocol (PP) analysis.18 ACPR 
is defined as the absence of clinical and parasitological 
malaria until day 42. The subject who unable to 
meet ACPR was considered either Early Treatment 
Failure (ETF), Late Clinical Failure (LCF).or Late 
Parasitological Failure (LPF).18 Subjects lost to follow 
up, withdrawal of consent and protocol violations  were 
considered censored events until day 42 according 
WHO guideline 2009.18 ITT is defined as analysis on 
all the subjects who were recruited and take at least 
one dose of the study drug; while PP is defined as 
analysis on all subject who finished the study regimen. 
The protocol violation was defined as all the subject 
who unable to meet inclusion and exclusion criteria 
including the new infection with different species.15
Safety was performed based on a occurrence of 
adverse events that happened until d42 during 
AN and DHP treatment. Any clinical symptom in 
anyday of follow-up which never reported at day 
recruitment(d0) was considered as an adverse event. 
Other parameters measured such as proportion 
of clinical symptom, parasite clearance time and 
gametocyte clearances were analyzed by chi-square 
test and t-test or mann-whitney test.  Proportion 
of clinical symptom was define as any clinical 
symptom at day of recruitment according to standard 
clinical malaria manifestation.18 Proportion of asexsual 
parasitemia and gametocytes werecalculated for each 
eight-hour intervaluntil hour 72 (d72), gametocytes 
would be countinued especially each seven-days 
interval until day 42(d42). Proportion of parasite 
clearance was measured for regression models of the 
log transformed parasite counts were fitted in order to 
estimate parasite clearance using the Parasite Clearance 
Estimator Tool (PCE) developed by the World Wide 
Antimalarial Resistance Network (WWARN).19
The study received ethical approval by the Ethics 
Commission of the National Institute of Health 
Research and Development, Ministry of Health, 
Indonesia with no. LB.03.02/2/449/2007. and The 
Bureau of Food and Drug Control Republic of 
Indonesia with no. PO.01.01.3.1.1682
RESULTS 
A total of 158 subjects were included in the study with 
80 subjects treated with AN and 78 with DHP (figure 
1). In the AN group two cases (2.5%) were analysed as 
protocol violations, one  due to the ingestion of other 
antimalarial drugs on the d28, and the other because of 
failure classified as Late Parasitological Failure (LPF) 
with a different species (P.falciparum) on d32. In DHP 
group two cases (2.6%) were analysed as withdrawn 
consent on d0 and d4 and two cases (2.6%) as protocol 
violations with LPF of different species (P.falciparum) 
on day 35. Additionally, three cases in the AN group 
and four cases in the DHP group were lost to follow-up 
(LTFU). Primaquine was given to all subject. 
The baseline characteristics of the two study groups 
were similar such as sex and fever (table 1). The 
clinical symptom characteristics at day of admission 
were similar (table 2). History of vomiting was 
reported in more than 20 % of the subjects in AN 
group compared to DHP (22.5% vs 6.4%. p = 0.008).
The proportion of parasitemia at eight-hour intervals 
from 0 until 72 hours can be found in figure 1.  The 
median parasite clearance estimator (PCE) was 2.32 
(range: 1.42 – 7.78 ; IQR: 1.99 – 2.82) hours with 
median PC50 2.98 (range: 0.11 – 11.59) hours and 
median PC90 8.41 (range: 4.22 – 24.32) hours after AN 
treatment. While the median PCE after DP treatment 
was 2.05 (range: 1.30 – 8.30 ; IQR: 1.82 – 2.46) hours 
with median PC50 2.00 (range:0.07 – 14.88) hours 
and median PC90 6.22 (range 3.23 -22.58) hours. 
Gametocyte clearance was not evidence until 72 
hours after treatment for both of drugs (figure 2). All 
subjects obtained   gametocyte clearance on day 21 in 
the AN group and on day 7 in the DHP group.
The ACPR of both drugs on d42 based on ITT and PP 
analysis was 100% (95% CI: 95.2 –100)  for AN  and 
100%, 95% CI: 94.9 – 100 for DHP. There was no ETF, 
LCF or LPF with P. Vivax following reccurence cases in 
both treatment arm. Confidence intervals measures for 
ACPR were by exact binomial method for PP analysis 
or beta product confidence procedure for ITT analysis 
and were equivalent because there was 100% response.20
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A few adverse events were reported during this study. 
The most commonly reported adverse events in the 
AN group were nausea 6.3%(5/80), abdominal pain 
5%(4/80), fatigue 3.8%(3/80), cough 3.8%(3/80), 
dizzy 7.5%(6/80), sleep disturbance 6.3%(5/80) and 
rigors 5%(4/80).The most common adverse events 
reported in the DHP group were fatigue 9.1% (7/77).
cough 2.6% (2/77),dizzy 3.9%(3/77), vomiting7.8% 
(6/77) and abdominal pain 2.6% (2/77).
DISCUSSION 
Our study shows AN and DHP had similar efficacy 
with 100 percent ACPR in all subjects with P.vivax 
at day 42.This demonstrated that both drugs have 
essentially fulfilled the WHO criteria in that the 
percentage of efficacy is higher than 95%. Both 
drugs also show similar safety profile.
This study is consistent with other AN and DHP 
studies and confirmed that AN as a single drug can 
be a potential alternative for treating infection with P. 
vivax.11.15 In our study the reccurence of P. Vivax was 
not found. Gametocytemia was found in more than 80 
percent of patients at baseline which is  characteristic 
of the sexual stage of P. vivax infection.21 Both drugs 
can eliminate the gametocyte but gametocytemia was 
found in a few cases after 72 hours of treatment so the 
transmission could potentially continue. Prolonged 
gametocytemia in P. falciparum and P. vivax treatment 
could be one of many signs of recurrent parasitemia 
although in this study we observed no reccurence.21.22 
The submicrocopic parasitemia study might be 
required in the future to detect the gametocytopenia 
level at the end of the treatment study.  Because of this 
the primaquine was needed in the early treatment with 
ACTs. Primaquine can diminish asexual stage for all 
of Plasmodium species in humans. 
The median PCE, PC50 and PC90 of DHP were faster 
than AN.The data conformed another study of an 
artemisinin derivative.5.11.12.23Artemisinin derivative 
was a fast acting drug including dihydroarteminin 
and artemisinin. However dihydroartemisinin showed 
higher activity and had parasite clearance time 
faster compare artemisinin.23.24 The parasitemia was 
clear at 64 hours for all subjects in both treatment. 
This shows that AN as a single-dose and DHP as a 
three-dose daily drugs have a similar anti-parasitic 
potential. Artemisinin derivatives can eliminate the 
parasitemia immediately, but if administered alone as 
Table 1. Several baseline characteristics of subjects
Characteristic Artemisinin+ 
Napthoquine
DihydroArtemisinin+
Piperaquine P
Number of subject (n=80) (n=78)
Males (%) 91.3 82.1 0.142
History of Fever (%) 97.5 98.7 1.000
Fever ≥ 37.5 oC (%) 56.3 55.1 1.000
Laboratory
Geometric mean  (95%CI)  parasitemiain par/ul
4769 
(3751 – 6002)
4628 
(3640 – 6002) 0.874
Geometric mean  (95%CI) gametocytemiain par/ul
40 
(30 – 54)
33 
(25 – 44) 0.303
Gametocytemia (%) 88.8 92.3 0.623
Median (range) haemoglobin in g/dl 13 (7.3 – 23.1) 13 (7.5 – 16.4) 0.523
Anemia group (Hb<11 g/dl)  (%) 13.8 17.9 0.518
Median (range) age in years 23 (16 – 62) 23 (16 -64) 0.490
Median (range) body weight in Kg 60 (39 – 81) 58.5 (41 -75) 0.153
Table 2. Several clinical manifestation characteristics of 
subjects
Clinical Symptom Artemisinin+ 
Napthoquine
Artemisinin+
Piperaquine
P
Diarrhea 3.8 0.0 0.245
Palpitations 7.5 3.8 0.517
Cough   7.5 10.3 0.742
Abdominal pain 10.0 10.3 1.000
Anorexia 12.5 14.1 0.950
Sleep disturbance 13.8 11.5 0.858
Unwell 21.3 25.6 0.643
Sweating 21.3 29.5 0.314
Vomiting 22.5 6.4 0.008
Myalgia 23.8 37.2 0.096
Fatigue 23.8 19.2 0.619
Dizzy 41.3 34.6 0.487
Rigors/chills 52.5 50.0 0.877
Headache     53.8 51.3 0.880
Nausea     58.8 51.3 0.433
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monotherapy, it must be given for 5 – 7 days because of 
rapid drug elimination. This disadvantage exists even 
with a small parasitemia count, but it can be overcome 
by co-administration of Napthoquine, which results in 
adequate parasite clearance time and protection from 
early recurrence. Moreover, artemisinin resistance for 
P. vivax has not been reported yet in Indonesia.
The adverse events were categorized as mild in this study 
for both treatments. This is consistent with the other 
studies.5.11.15All adverse events were related to the drugs. 
Both drugs were tolerated well, despite high numbers of 
cases in the AN group reporting vomiting at baseline. This 
shows that both drugs did not given any severe effect. 
The limitations of our study were a small sample size 
and inclusion of only adults. This study was a part 
of main study for all malaria cases,15 and was giving 
us information related the efficacy and safety of AN 
for treatment P.vivax infection. The inclusion of only 
adults was related with AN as a new drug, so the 
children study for AN was needed to use this drug as 
an alternative of malaria treatment widely. The study 
had more male subjects than females because we 
conducted the study at four hospitals and three were 
armed forces hospitals, which primarily serve men. 
Eventhough, there was no different cases between 
men and women for malaria vivax infection.
Figure 1. Subject flow diagram
Pv = Plasmodium vivax; LTFU= lost to follow up; PP= per protocol;
* = Reference number 15
Figure 2. Proportion of asexsual parasitemia in hours
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In conclusion, both drugs had similar efficacy and 
safety profiles for the treatment of vivax malaria 
in adult subjects in hospitals in Indonesia and 
fulfills WHO criteria. AN took longer to clear 
the parasitemia than DHP but parasite clearance 
was complete in all patients by 64 hours. Further 
evaluation studies are still needed at Primary Health 
Care centers, especially for  efficacy and safety  for 
children. This study supports the recommendation of 
AN as an alternative drug for P. vivax malaria.
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